Cargando…

Pulmonary surfactant and COVID-19: A new synthesis

CHAPTER 1: COVID-19 pathogenesis poses paradoxes difficult to explain with traditional physiology. For instance, since type II pneumocytes are considered the primary cellular target of SARS-CoV-2; as these produce pulmonary surfactant (PS), the possibility that insufficient PS plays a role in COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ninham, Barry, Reines, Brandon, Battye, Matthew, Thomas, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411325/
https://www.ncbi.nlm.nih.gov/pubmed/37564950
http://dx.doi.org/10.1017/qrd.2022.1
_version_ 1785086640971055104
author Ninham, Barry
Reines, Brandon
Battye, Matthew
Thomas, Paul
author_facet Ninham, Barry
Reines, Brandon
Battye, Matthew
Thomas, Paul
author_sort Ninham, Barry
collection PubMed
description CHAPTER 1: COVID-19 pathogenesis poses paradoxes difficult to explain with traditional physiology. For instance, since type II pneumocytes are considered the primary cellular target of SARS-CoV-2; as these produce pulmonary surfactant (PS), the possibility that insufficient PS plays a role in COVID-19 pathogenesis has been raised. However, the opposite of predicted high alveolar surface tension is found in many early COVID-19 patients: paradoxically normal lung volumes and high compliance occur, with profound hypoxemia. That ‘COVID anomaly’ was quickly rationalised by invoking traditional vascular mechanisms–mainly because of surprisingly preserved alveolar surface in early hypoxemic cases. However, that quick rejection of alveolar damage only occurred because the actual mechanism of gas exchange has long been presumed to be non-problematic, due to diffusion through the alveolar surface. On the contrary, we provide physical chemical evidence that gas exchange occurs by an process of expansion and contraction of the three-dimensional structures of PS and its associated proteins. This view explains anomalous observations from the level of cryo-TEM to whole individuals. It encompasses results from premature infants to the deepest diving seals. Once understood, the COVID anomaly dissolves and is straightforwardly explained as covert viral damage to the 3D structure of PS, with direct treatment implications. As a natural experiment, the SARS-CoV-2 virus itself has helped us to simplify and clarify not only the nature of dyspnea and its relationship to pulmonary compliance, but also the fine detail of the PS including such features as water channels which had heretofore been entirely unexpected. CHAPTER 2: For a long time, physical, colloid and surface chemistry have not intersected with physiology and cell biology as much as we might have hoped. The reasons are starting to become clear. The discipline of physical chemistry suffered from serious unrecognised omissions that rendered it ineffective. These foundational defects included omission of specific ion molecular forces and hydration effects. The discipline lacked a predictive theory of self-assembly of lipids and proteins. Worse, theory omitted any role for dissolved gases, O(2), N(2), CO(2), and their existence as stable nanobubbles above physiological salt concentration. Recent developments have gone some way to explaining the foam-like lung surfactant structures and function. It delivers O(2)/N(2) as nanobubbles, and efflux of CO(2), and H(2)O nanobubbles at the alveolar surface. Knowledge of pulmonary surfactant structure allows an explanation of the mechanism of corona virus entry, and differences in infectivity of different variants. CO(2) nanobubbles, resulting from metabolism passing through the molecular frit provided by the glycocalyx of venous tissue, forms the previously unexplained foam which is the endothelial surface layer. CO(2) nanobubbles turn out to be lethal to viruses, providing a plausible explanation for the origin of ‘Long COVID’. Circulating nanobubbles, stable above physiological 0.17 M salt drive various enzyme-like activities and chemical reactions. Awareness of the microstructure of Pulmonary Surfactant and that nanobubbles of (O(2)/N(2)) and CO(2) are integral to respiratory and circulatory physiology provides new insights to the COVID-19 and other pathogen activity.
format Online
Article
Text
id pubmed-10411325
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-104113252023-08-10 Pulmonary surfactant and COVID-19: A new synthesis Ninham, Barry Reines, Brandon Battye, Matthew Thomas, Paul QRB Discov Research Article CHAPTER 1: COVID-19 pathogenesis poses paradoxes difficult to explain with traditional physiology. For instance, since type II pneumocytes are considered the primary cellular target of SARS-CoV-2; as these produce pulmonary surfactant (PS), the possibility that insufficient PS plays a role in COVID-19 pathogenesis has been raised. However, the opposite of predicted high alveolar surface tension is found in many early COVID-19 patients: paradoxically normal lung volumes and high compliance occur, with profound hypoxemia. That ‘COVID anomaly’ was quickly rationalised by invoking traditional vascular mechanisms–mainly because of surprisingly preserved alveolar surface in early hypoxemic cases. However, that quick rejection of alveolar damage only occurred because the actual mechanism of gas exchange has long been presumed to be non-problematic, due to diffusion through the alveolar surface. On the contrary, we provide physical chemical evidence that gas exchange occurs by an process of expansion and contraction of the three-dimensional structures of PS and its associated proteins. This view explains anomalous observations from the level of cryo-TEM to whole individuals. It encompasses results from premature infants to the deepest diving seals. Once understood, the COVID anomaly dissolves and is straightforwardly explained as covert viral damage to the 3D structure of PS, with direct treatment implications. As a natural experiment, the SARS-CoV-2 virus itself has helped us to simplify and clarify not only the nature of dyspnea and its relationship to pulmonary compliance, but also the fine detail of the PS including such features as water channels which had heretofore been entirely unexpected. CHAPTER 2: For a long time, physical, colloid and surface chemistry have not intersected with physiology and cell biology as much as we might have hoped. The reasons are starting to become clear. The discipline of physical chemistry suffered from serious unrecognised omissions that rendered it ineffective. These foundational defects included omission of specific ion molecular forces and hydration effects. The discipline lacked a predictive theory of self-assembly of lipids and proteins. Worse, theory omitted any role for dissolved gases, O(2), N(2), CO(2), and their existence as stable nanobubbles above physiological salt concentration. Recent developments have gone some way to explaining the foam-like lung surfactant structures and function. It delivers O(2)/N(2) as nanobubbles, and efflux of CO(2), and H(2)O nanobubbles at the alveolar surface. Knowledge of pulmonary surfactant structure allows an explanation of the mechanism of corona virus entry, and differences in infectivity of different variants. CO(2) nanobubbles, resulting from metabolism passing through the molecular frit provided by the glycocalyx of venous tissue, forms the previously unexplained foam which is the endothelial surface layer. CO(2) nanobubbles turn out to be lethal to viruses, providing a plausible explanation for the origin of ‘Long COVID’. Circulating nanobubbles, stable above physiological 0.17 M salt drive various enzyme-like activities and chemical reactions. Awareness of the microstructure of Pulmonary Surfactant and that nanobubbles of (O(2)/N(2)) and CO(2) are integral to respiratory and circulatory physiology provides new insights to the COVID-19 and other pathogen activity. Cambridge University Press 2022-04-22 /pmc/articles/PMC10411325/ /pubmed/37564950 http://dx.doi.org/10.1017/qrd.2022.1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Research Article
Ninham, Barry
Reines, Brandon
Battye, Matthew
Thomas, Paul
Pulmonary surfactant and COVID-19: A new synthesis
title Pulmonary surfactant and COVID-19: A new synthesis
title_full Pulmonary surfactant and COVID-19: A new synthesis
title_fullStr Pulmonary surfactant and COVID-19: A new synthesis
title_full_unstemmed Pulmonary surfactant and COVID-19: A new synthesis
title_short Pulmonary surfactant and COVID-19: A new synthesis
title_sort pulmonary surfactant and covid-19: a new synthesis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411325/
https://www.ncbi.nlm.nih.gov/pubmed/37564950
http://dx.doi.org/10.1017/qrd.2022.1
work_keys_str_mv AT ninhambarry pulmonarysurfactantandcovid19anewsynthesis
AT reinesbrandon pulmonarysurfactantandcovid19anewsynthesis
AT battyematthew pulmonarysurfactantandcovid19anewsynthesis
AT thomaspaul pulmonarysurfactantandcovid19anewsynthesis